Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Cellular immune controls over Epstein-Barr virus infection: new lessons from the clinic and the laboratory.

Rickinson AB, Long HM, Palendira U, Münz C, Hislop AD.

Trends Immunol. 2014 Apr;35(4):159-69. doi: 10.1016/j.it.2014.01.003. Epub 2014 Mar 1. Review.

PMID:
24589417
2.

The immunology of Epstein-Barr virus-induced disease.

Taylor GS, Long HM, Brooks JM, Rickinson AB, Hislop AD.

Annu Rev Immunol. 2015;33:787-821. doi: 10.1146/annurev-immunol-032414-112326. Epub 2015 Feb 11. Review.

PMID:
25706097
3.

Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.

Wang Y, Aïssi-Rothe L, Virion JM, De Carvalho Bittencourt M, Ulas N, Audonnet S, Salmon A, Clement L, Venard V, Jeulin H, Stoltz JF, Decot V, Bensoussan D.

Cytotherapy. 2014 Jan;16(1):122-34. doi: 10.1016/j.jcyt.2013.07.008. Epub 2013 Oct 1.

PMID:
24094498
4.

A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses.

Yajima M, Imadome K, Nakagawa A, Watanabe S, Terashima K, Nakamura H, Ito M, Shimizu N, Honda M, Yamamoto N, Fujiwara S.

J Infect Dis. 2008 Sep 1;198(5):673-82. doi: 10.1086/590502.

PMID:
18627269
5.

Animal models of Epstein Barr virus infection.

Chatterjee B, Leung CS, Münz C.

J Immunol Methods. 2014 Aug;410:80-7. doi: 10.1016/j.jim.2014.04.009. Epub 2014 May 9.

PMID:
24815603
6.

Studying Epstein-Barr virus pathologies and immune surveillance by reconstructing EBV infection in mice.

Yasuda T, Wirtz T, Zhang B, Wunderlich T, Schmidt-Supprian M, Sommermann T, Rajewsky K.

Cold Spring Harb Symp Quant Biol. 2013;78:259-63. doi: 10.1101/sqb.2013.78.020222. Epub 2013 Nov 15.

PMID:
24241423
8.

Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus.

Islas-Ohlmayer M, Padgett-Thomas A, Domiati-Saad R, Melkus MW, Cravens PD, Martin Mdel P, Netto G, Garcia JV.

J Virol. 2004 Dec;78(24):13891-900.

9.

Nonhuman primate models for Epstein-Barr virus infection.

Wang F.

Curr Opin Virol. 2013 Jun;3(3):233-7. doi: 10.1016/j.coviro.2013.03.003. Epub 2013 Apr 3. Review.

10.

Spectrum of Epstein-Barr virus-associated T-cell lymphoproliferative disorder in adolescents and young adults in Taiwan.

Wang RC, Chang ST, Hsieh YC, Huang WT, Hsu JD, Tseng CE, Wang MC, Hwang WS, Wang J, Chuang SS.

Int J Clin Exp Pathol. 2014 Apr 15;7(5):2430-7. eCollection 2014.

11.

Immune defence against EBV and EBV-associated disease.

Long HM, Taylor GS, Rickinson AB.

Curr Opin Immunol. 2011 Apr;23(2):258-64. doi: 10.1016/j.coi.2010.12.014. Epub 2011 Jan 25. Review.

PMID:
21269819
12.

T/NK cell type chronic active Epstein-Barr virus disease in adults: an underlying condition for Epstein-Barr virus-associated T/NK-cell lymphoma.

Isobe Y, Aritaka N, Setoguchi Y, Ito Y, Kimura H, Hamano Y, Sugimoto K, Komatsu N.

J Clin Pathol. 2012 Mar;65(3):278-82. doi: 10.1136/jclinpath-2011-200523. Epub 2012 Jan 13.

PMID:
22247563
13.

GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder.

Baiocchi RA, Ward JS, Carrodeguas L, Eisenbeis CF, Peng R, Roychowdhury S, Vourganti S, Sekula T, O'Brien M, Moeschberger M, Caligiuri MA.

J Clin Invest. 2001 Sep;108(6):887-94.

14.

Immune Evasion by Epstein-Barr Virus.

Ressing ME, van Gent M, Gram AM, Hooykaas MJ, Piersma SJ, Wiertz EJ.

Curr Top Microbiol Immunol. 2015;391:355-81. doi: 10.1007/978-3-319-22834-1_12. Review.

PMID:
26428381
15.

CD4+ T cell responses in the immune control against latent infection by Epstein-Barr virus.

Paludan C, Münz C.

Curr Mol Med. 2003 Jun;3(4):341-7. Review.

PMID:
12776989
16.

A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas.

Ma SD, Hegde S, Young KH, Sullivan R, Rajesh D, Zhou Y, Jankowska-Gan E, Burlingham WJ, Sun X, Gulley ML, Tang W, Gumperz JE, Kenney SC.

J Virol. 2011 Jan;85(1):165-77. doi: 10.1128/JVI.01512-10. Epub 2010 Oct 27.

17.

Antibodies to lytic infection proteins in lymphocryptovirus-infected rhesus macaques: a model for humoral immune responses to epstein-barr virus infection.

Orlova N, Fogg MH, Carville A, Wang F.

Clin Vaccine Immunol. 2011 Sep;18(9):1427-34. doi: 10.1128/CVI.05126-11. Epub 2011 Jul 6.

18.

Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.

Niller HH, Wolf H, Minarovits J.

Autoimmunity. 2008 May;41(4):298-328. doi: 10.1080/08916930802024772. Review.

PMID:
18432410
19.

Immunological aspects of Epstein-Barr virus infection.

Ohga S, Nomura A, Takada H, Hara T.

Crit Rev Oncol Hematol. 2002 Dec;44(3):203-15. Review.

PMID:
12467961
20.

Primary immunodeficiencies predisposed to Epstein-Barr virus-driven haematological diseases.

Parvaneh N, Filipovich AH, Borkhardt A.

Br J Haematol. 2013 Sep;162(5):573-86. doi: 10.1111/bjh.12422. Epub 2013 Jun 11. Review.

PMID:
23758097

Supplemental Content

Support Center